Sector News

GSK to shutter Ermington plant in Australia by 2020

November 9, 2016
Life sciences

Pharma giant GlaxoSmithKline said it plans to shutter its over-the-counter consumer healthcare manufacturing facility in Ermington, Australia, by 2020. The closure will affect about 223 jobs, the company said.

The plant, which is located on the outskirts of Sydney, produces liquid and tablet cold and flu drugs mostly for the Australian market.

Citing a review of the facility that indicated it would not be able to remain competitive in the future without a “significant investment,” the company said it will institute a phased closure over the next four years that will include the transfer of some production to other GSK plants or to CMOs.

The closure of the Ermington plant isn’t expected to impact other GSK operations in the country, which include the manufacturing site in Boronia that produces respiratory products.

“We have thoroughly evaluated a number of options before taking the decision to close the site, but unfortunately significant ongoing investment would be needed to maintain our Ermington manufacturing facility, making it uncompetitive to keep manufacturing in Ermington in the future,” Michael Tyler, GSK’s vice president of supply chain in Asia, the Middle East and Africa, said in a statement.

Late last year, GSK opened a cutting-edge $5.7 million blow-fill-seal plant in Boronia, outside of Melbourne. That opening came on the heels of the company selling two opiate manufacturing sites to Indian generics maker Sun Pharma that are located in Latrobe, Tasmania, and Port Fairy, Victoria.

By Joseph Keenan

Source: Fierce Pharma

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”